Natures Sunshine Products
NATR on Nasdaq. Nature's Sunshine Products sells nutritional and personal care products to independent consultants. Market value $218m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
What to watch out for
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $8.29 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 59 of 100. Price score: 83 of 100. Our list needs 70 on quality and 60 on price.
$12.40 a share, at its 1-year low
Over the past year the price has ranged from $12.31 to $28.14.
Pays no dividend
Prices from Monday’s close (5 October).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $18 million in the past 12 months, $29 million in the year to December 2025.
| Revenue | |||||
| Revenue | $444m | $422m | $445m | $454m | $480m |
| Operating margin | |||||
| Operating margin | 7.8% | 3.9% | 4.2% | 4.4% | 5.2% |
| Debt to equity | |||||
| Debt to equity | 0.01 | 0.01 | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.02bn | 0.02bn | 0.02bn | 0.02bn | 0.02bn |
Health checks
- Free cash flow positive4 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)6 of 8 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsSlow, 4.5% a year
- Buying back its own sharesYes, 8% fewer since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $117 million last quarter, up 2% on a year ago.
- Profit: $4 million, down 34% on a year ago.
- It keeps 6 cents of each $1 of sales as operating profit, up from 4 cents a year earlier.
- Spare cash over the past 12 months: $18 million, down from $22 million.
- 3% fewer shares than a year ago. Each share owns a bit more of the company.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $115m |
| December 2024 | $118m |
| March 2025 | $113m |
| June 2025 | $115m |
| September 2025 | $128m |
| December 2025 | $124m |
| March 2026 | $123m |
| June 2026 | $117m |
| Quarter to | Amount |
|---|---|
| September 2024 | $4m |
| December 2024 | -$321,000 |
| March 2025 | $5m |
| June 2025 | $5m |
| September 2025 | $5m |
| December 2025 | $4m |
| March 2026 | $5m |
| June 2026 | $4m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 10 March 2026
- Next quarterly (estimated, 10-Q)
- 5 November 2026
Who owns it
3 long-term investors we follow own it, unchanged from 3 last quarter. 153 funds in all.
- LSV Asset ManagementJosef Lakonishok
- Value
- $433,000
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Boston PartnersBoston Partners team | $6m | <0.1% | Added |
| First Eagle Investment ManagementMatthew McLennan | $4m | <0.1% | Added |
| LSV Asset ManagementJosef Lakonishok | $433,000 | <0.1% |
Largest holders overall
- Wynnefield Capital$54m
- Prescott Group Capital Management, L.L.C.$39m
- BlackRock$22mCut
- Dimensional Fund Advisors LP$20mAdded
- American Century Companies$16mAdded
- Acadian Asset Management$15mAdded
- Kennedy Capital Management$14mCut
- Vanguard Capital Management$13m
- Renaissance Technologies$12m
- Geode Capital Management$8m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
4 investors own more than 5%.
- Fosun Pharma USA Inc.Passive investor15.6%Since 5 June 2025
What they said
Item 4 of the Schedule 13D is amended by adding the following information: On June 5, 2025, Fosun Pharma contributed 2,854,607 shares of Common Stock to FPUSA. The Reporting Persons may dispose or continue to hold all or a portion of the shares of Common Stock reported herein,…
Read the filing - PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.Passive investorat least 10.9%(filed with 4 related holders)Since 6 August 2026
- Dimensional Fund Advisors LPPassive investor5.2%Since 30 September 2025
- BlackRock, Inc.Passive investor5.0%Since 30 September 2025
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.Sold down below 5%Since 25 June 2025
What they said
Item 4 is hereby amended by adding the following paragraphs: On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of…
Read the filing
| Holder | Stake | Since | |
|---|---|---|---|
Fosun Pharma USA Inc. Passive investor | 15.6% | 5 June 2025 | What they saidItem 4 of the Schedule 13D is amended by adding the following information: On June 5, 2025, Fosun Pharma contributed 2,854,607 shares of Common Stock to FPUSA. The Reporting Persons may dispose or continue to hold all or a portion of the shares of Common Stock reported herein,… Read the filing |
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. Passive investor | at least 10.9% (filed with 4 related holders) | 6 August 2026 | |
Dimensional Fund Advisors LP Passive investor | 5.2% | 30 September 2025 | |
BlackRock, Inc. Passive investor | 5.0% | 30 September 2025 | |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | Sold down below 5% | 25 June 2025 | What they saidItem 4 is hereby amended by adding the following paragraphs: On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of… Read the filing |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 5 sold $2m.
- Herbert Kevin R.EVP & President, North AmericaSold
- Date
- 12 June 2026
- Shares
- 2,000
- Price
- $20.68
- Value
- $41,364
- Yates Bryant JEVP & President, EuropeSold
- Date
- 5 June 2026
- Shares
- 11,968
- Price
- $19.90
- Value
- $238,163
- Norman Daniel CEVP & President, AsiaSold
- Date
- 1 June 2026
- Shares
- 9,713
- Price
- $20.64
- Value
- $200,476
- Brower Nathan GEVP, General CounselSold
- Date
- 21 May 2026
- Shares
- 12,015
- Price
- $21.84
- Value
- $262,408
- Yates Bryant JEVP & President, EuropeSold
- Date
- 13 March 2026
- Shares
- 19,516
- Price
- $24.35
- Value
- $475,215
- Norman Daniel CEVP & President, AsiaSold
- Date
- 13 March 2026
- Shares
- 15,383
- Price
- $24.52
- Value
- $377,191
- Lanoy Jonathan DavidSVP, Chief Accounting OfficerSold
- Date
- 13 March 2026
- Shares
- 4,000
- Price
- $24.70
- Value
- $98,800
- Yates Bryant JEVP & President, EuropeSold
- Date
- 12 December 2025
- Shares
- 1,700
- Price
- $22.29
- Value
- $37,893
- Lanoy Jonathan DavidSVP, Chief Accounting OfficerSold
- Date
- 18 November 2025
- Shares
- 5,000
- Price
- $20.45
- Value
- $102,250
- Brower Nathan GEVP, General CounselSold
- Date
- 14 November 2025
- Shares
- 3,800
- Price
- $20.81
- Value
- $79,078
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 12 June 2026 | Herbert Kevin R. EVP & President, North America | Sold | 2,000 | $20.68 | $41,364 |
| 5 June 2026 | Yates Bryant J EVP & President, Europe | Sold | 11,968 | $19.90 | $238,163 |
| 1 June 2026 | Norman Daniel C EVP & President, Asia | Sold | 9,713 | $20.64 | $200,476 |
| 21 May 2026 | Brower Nathan G EVP, General Counsel | Sold | 12,015 | $21.84 | $262,408 |
| 13 March 2026 | Yates Bryant J EVP & President, Europe | Sold | 19,516 | $24.35 | $475,215 |
| 13 March 2026 | Norman Daniel C EVP & President, Asia | Sold | 15,383 | $24.52 | $377,191 |
| 13 March 2026 | Lanoy Jonathan David SVP, Chief Accounting Officer | Sold | 4,000 | $24.70 | $98,800 |
| 12 December 2025 | Yates Bryant J EVP & President, Europe | Sold | 1,700 | $22.29 | $37,893 |
| 18 November 2025 | Lanoy Jonathan David SVP, Chief Accounting Officer | Sold | 5,000 | $20.45 | $102,250 |
| 14 November 2025 | Brower Nathan G EVP, General Counsel | Sold | 3,800 | $20.81 | $79,078 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Mar 2026, plus the 10-Q filed 6 Aug 2026 and 3 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.